Clinical observation of Chansu injection combined with EOAP regimen in patients with advanced non-Hodgkin lymphoma

Abstract

Objective To evaluate the efficacy and safety of Chansu injection (CHS) combined with EOAP regimen in patients with advanced non-Hodgkin lymphoma (NHL). Methods 65 patients with advanced NHL were divided into two groups according to random number table. All were given EOAP regimen (VP16 60 mg/m2 on d 1-5; VCR 1.4 mg/m2 on d1; Ara-C 60 mg/m2, Q12 h, on d 1-5; Pred 60 mg/m2 on d 1-5), and the observation group received EOAP combined with CHS (20 ml/d, intravenous drip, on d 1-14). The regimen was repeated every 21 days. The efficacy and toxicity were evaluated after two cycles. Results The effective rate of the observation group was higher than that of the control group, but there was no significant difference between two groups [87.9 % (29/33) vs 81.3 % (26/32), P > 0.05]. The quality of life of the observation group was superior to that of the control group, and there was significant difference (P < 0.05). Hematological toxicities and gastrointestinal tract reaction were the main side effects in both groups. The incidence of myelosuppression of the observation group was significantly lower than that of the control group (P < 0.05). Conclusion Chansu injection combined with EOAP regimen can enhance the efficacy, reduce toxicity and improve the quality of life in the treatment of advanced NHL. Key words: Lymphoma, non-Hodgkin; Chansu injection; Antineoplastic combined chemotherapy protocols